Published in Expert Opin Pharmacother on January 01, 2015
Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity. J Korean Med Sci (2017) 0.77
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Associated with Risk of Pulmonary Embolism. PLoS One (2016) 0.75
A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Advances in understanding COPD. F1000Res (2016) 0.75
Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. PLoS One (2016) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Chronic obstructive pulmonary disease. N Engl J Med (2000) 8.23
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med (2007) 8.06
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med (2000) 5.65
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.82
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet (1994) 4.77
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med (2013) 4.22
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med (2007) 3.94
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 3.90
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med (2015) 3.74
Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax (2013) 3.62
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med (2012) 3.51
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J (2014) 3.48
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med (2013) 2.92
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med (2002) 2.92
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J (2007) 2.78
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med (2013) 2.75
Methodological issues in therapeutic trials of COPD. Eur Respir J (2008) 2.69
Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax (2011) 2.59
Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J (2015) 2.45
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2014) 2.41
The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J (2014) 2.27
Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol (2014) 2.15
Factors associated with bronchiectasis in patients with COPD. Chest (2011) 2.14
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med (2015) 2.13
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J (2009) 2.11
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med (2012) 1.85
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax (2005) 1.81
Use of inhaled corticosteroids and the risk of tuberculosis. Thorax (2013) 1.77
The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J (2013) 1.72
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J (2003) 1.70
Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.68
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med (2010) 1.66
Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax (2000) 1.65
Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med (2009) 1.60
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev (2014) 1.56
An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med (1999) 1.46
Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.44
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J (2006) 1.40
Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax (1999) 1.34
Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J (1993) 1.32
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol (1999) 1.27
The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med (2015) 1.25
Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med (2014) 1.23
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J (2006) 1.20
Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest (2008) 1.19
Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J (2014) 1.17
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med (2014) 1.14
Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res (2014) 1.12
Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J (2013) 1.12
Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract (2011) 1.11
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.02
Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther (2004) 1.00
Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 0.99
Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med (2011) 0.98
Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med (2014) 0.98
Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res (2007) 0.98
Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res (2014) 0.97
Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther (2008) 0.96
Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem (2013) 0.95
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J (2014) 0.92
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2013) 0.91
Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today (2014) 0.90
Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest (2004) 0.89
Stepping down therapy in COPD. N Engl J Med (2014) 0.89
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? COPD (2009) 0.85
Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open (2013) 0.85
Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population. Respir Med (2014) 0.85
Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem (2013) 0.83
Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.82
Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol (2011) 0.81
Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis. Respir Res (2014) 0.80
Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respir Res (2014) 0.78
The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch Bronconeumol (2012) 0.77
Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respir Med (2012) 0.76
Methodological issues in therapeutic trials of COPD. Eur Respir J (2009) 0.75
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother (2005) 7.42
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology (2012) 4.83
Chronic obstructive pulmonary disease. Lancet (2012) 4.43
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med (2006) 4.20
European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl (2012) 3.98
Privatising primary care. Br J Gen Pract (2006) 3.68
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 3.61
The public health implications of world trade negotiations on the general agreement on trade in services and public services. Lancet (2003) 3.52
The future of peptide-based drugs. Chem Biol Drug Des (2013) 3.41
Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ (2003) 2.93
Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.41
Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care. Chest (2009) 2.35
Family medicine in 2018. Can Fam Physician (2010) 2.24
Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J (2012) 2.18
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med (2006) 2.10
COPD screening efforts in primary care: what is the yield? Prim Care Respir J (2007) 2.03
Screening for and early detection of chronic obstructive pulmonary disease. Lancet (2009) 1.99
No evidence that patient choice in the NHS saves lives. Lancet (2011) 1.96
Bronchodilator reversibility in COPD. Chest (2011) 1.89
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol (2004) 1.88
Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ (2012) 1.87
Role of living liver donation in the United Kingdom. BMJ (2003) 1.82
General practitioners with a special clinical interest: a model for improving respiratory disease management. Br J Gen Pract (2002) 1.80
Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res (2010) 1.79
High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol (2008) 1.76
The market in primary care. BMJ (2007) 1.73
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.70
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.70
Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol (2012) 1.68
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J (2011) 1.68
Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability. Prim Care Respir J (2007) 1.67
Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J (2009) 1.66
Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol (2010) 1.66
Reconsidering sex-based stereotypes of COPD. Prim Care Respir J (2011) 1.66
The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J (2009) 1.64
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration (2012) 1.62
A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther (2013) 1.61
Achieving asthma control in practice: understanding the reasons for poor control. Respir Med (2008) 1.61
The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J Antimicrob Chemother (2008) 1.60
Clinical trials and tribulations: the MASCOT study. Thorax (2011) 1.59
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Functional coupling of capping and transcription of mRNA. Mol Cell (2002) 1.56
Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med (2008) 1.55
Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. Br J Gen Pract (2005) 1.53
Professional and patient attitudes to using mobile phone technology to monitor asthma: questionnaire survey. Prim Care Respir J (2006) 1.52
Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest (2013) 1.51
The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J (2009) 1.51
Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med (2007) 1.51
Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Arch Bronconeumol (2011) 1.50
New deal from the World Trade Organisation. BMJ (2003) 1.49
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol (2007) 1.49
The national montelukast survey. J Allergy Clin Immunol (2005) 1.47
Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. Arch Bronconeumol (2013) 1.47
Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis (2012) 1.47
Percutaneous femoral arteriovenous shunt creation for advanced chronic obstructive pulmonary disease: a single-center safety and efficacy study. Circ Cardiovasc Interv (2012) 1.46
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med (2003) 1.44
Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics (2005) 1.42
Mid Staffordshire should lead to a fundamental rethink of government policy. BMJ (2013) 1.41
How the secretary of state for health proposes to abolish the NHS in England. BMJ (2011) 1.40
[Variability of antibiotic prescribing for respiratory tract infections in two European countries]. Enferm Infecc Microbiol Clin (2005) 1.39
GOLD COPD categories are not fit for purpose in primary care. Lancet Respir Med (2013) 1.37
Pro-con debate: Inhaled corticosteroids should not be prescribed in primary care to children under two years of age - the case for. Prim Care Respir J (2008) 1.37
Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics (2005) 1.36
Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med (2010) 1.33
Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc (2014) 1.32
Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc (2006) 1.32
Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis (2009) 1.32
EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 - a summary. Prim Care Respir J (2008) 1.31
The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med (2012) 1.26
ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol (2006) 1.26
Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain (2012) 1.25
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol (2009) 1.25
The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med (2015) 1.25
Asthma out of control? A structured review of recent patient surveys. BMC Pulm Med (2006) 1.24
Questions for COPD diagnostic screening in a primary care setting. Respir Med (2005) 1.23
Do symptoms predict COPD in smokers? Chest (2010) 1.22
Current control and future risk in asthma management. Allergy Asthma Immunol Res (2011) 1.22
How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England. Lancet (2012) 1.22
Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med (2010) 1.20
Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg (2002) 1.20
Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res (2011) 1.19
An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans. Prim Care Respir J (2007) 1.19
The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development. Lancet (2011) 1.19
Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. Inhal Toxicol (2008) 1.19
A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.18
Chronic obstructive pulmonary disease. BMJ (2003) 1.17
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Determinants of Underdiagnosis of COPD in National and International Surveys. Chest (2015) 1.14
British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med (2008) 1.14
High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer (2003) 1.13
Best cases from the AFIP: omental lymphangioma with small-bowel volvulus. Radiographics (2003) 1.13
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol (2012) 1.13
Befriending carers of people with dementia: randomised controlled trial. BMJ (2008) 1.12
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12